Five things for pharma marketers to know for Wednesday morning
Bluebird Bio plans to raise $250 million in a stock sale and unusual financing deal.
Source: mmm-online.com
Page 7 - Compugen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Compugen Today - Breaking & Trending Today
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody ...
Source: pharmiweb.com
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a...
Source: marketscreener.com
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen Ltd. announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig....
Source: marketscreener.com
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZenecaHOLON, Israel, Dec. 19, 2023 /PRNewswire/ --...
Source: marketscreener.com